Abstract
Renal osteodystrophy is a complex disorder expressing at the musculoskeletal level the metabolic abnormalities of renal disease (1). It is universally present in patients with chronic renal disease and continues to be one of the more difficult problems that confront the clinician charged with the responsibility of managing patients with chronic renal failure. A major difficulty in attempting to adopt a rational approach in these patients’ management has been the lack of a complete understanding of the pathogenesis of the deranged skeletal metabolism (2,3). Recently, development of morphometric analysis of bone biopsies, sensitive assays of vitamin D metabolites and parathormone (PTH), specific vitamin D metabolites for experimentation combined with formulation of testable hypotheses, have expanded our understanding of calcium and phosphorus homeostasis in renal osteodystrophy. New therapeutic trends, based on recent pathophysiologic information, can be perceived which have already changed the often dramatic clinical picture seen 10–15 years ago. Treatment of renal osteodystrophy undoubtedly will undergo much refinement within the next five years and its prevention appears as a reachable goal.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Kumar, B.: Renal osteodystrophy: A complex disorder. J. Lab. Clin. Med. 93: 995–897, 1979.
Coburn, J.W., Kurokawa, K. and Llach, F.: Altered divalent ion metabolism in renal disease and renal osteodystrophy. In: Maxwell, M.H. and Kleeman, C.R. (eds.): Clinical Disorders of Fluid and Electrolyte Metabolism. New York: McGraw Hill, 1980, pp. 1153–1251.
Kurokawa, K., Klein, K. and Hartenbower, D.L.: Disorders of calcium and phosphate homeostasis. In: Gonick, C. (ed.): Current Nephrology. New York: Houghton Mifflin, 1979, Vol. 3, pp. 135–197.
Avioli, L.V.: Renal osteodystrophy. In: Avioli, L.V. and Krane, S.M. (eds.): Metabolic Bone Disease. New York: Academic Press, 1978, Vol. 1, pp. 142–218.
de Graaf, P., Schicht, I.M., Pauwels, E.K.J, et al.: Bone scintigraphy in renal osteodystrophy. J. Nucl. Med. 19: 1289–1296, 1978.
Malluche, H.H., Ritz, H., Lange, H.P. et al.: Bone histology in incipient and advanced renal failure. Kidney Int. 9: 355–372, 1976.
Dent, C.E. and Stamp, T.C.B.: Vitamin D, rickets and osteomalacia. In: Avioli, L.V. and Krane, S.M. (eds.): Metabolic Bone Disease. New York: Academic Press, 1978, Vol. 1, pp. 237–302.
Bordier, P., Rasmussen, H., Marie, P. et al.: Vitamin D metabolites and bone mineralization in man. J. Clin. Endocrinol. Metab. 46: 284–294, 1978.
Habener, J.F. and Potts, J.T., Jr.: Parathyroid physiology and primary hyperparathyroidism. In: Avioli, L.V. and Krane, S.M. (eds.): Metabolic Bone Disease. New York: Academic Press, 1978, Vol. 1, pp. 1–149.
Kaplan, M.A., Canterbury, J.M., Gavallas, G. et al.: Interrelations between phosphorus, calcium, parathyroid hormone, and renal phosphate excretion in response to an oral phosphorus load in normal and uremic dogs. Kidney Int. 14: 207–214, 1978.
Reiss, E., Canterbury, J. and Kanter, A.: Circulating parathyroid hormone concentration in chronic renal insufficiency. Arch. Int. Med. 124: 417–422, 1969.
Slatopolsky, E., Rutherford, W.E., Hruska, K. et al.: How important is phosphate in the pathogenesis of renal osteodystrophy? Arch. Int. Med. 138: 848–852, 1978.
Massry, S.G. The pathogenesis of secondary hyperparathyroidism of renal failure. Is there a controversy? Arch. Int. Med. 138: 848–852, 1978.
Massry, S.G. Pathogenesis of secondary hyperparathyroidism in early renal failure: a multifactorial system including phosphate retention, skeletal resistance to PTH, and altered vitamin D metabolism. In: Norman, A.W. et al. (eds.): Vitamin D. Basic Research and its Clinical Application. New York: W. de Gruyter, 1979, pp. 1203–1208.
Slatopolsky, E., Gray, R., Adams, N.D. et al.: The pathogenesis of secondary hyperparathyroidism in early renal failure. In: Norman, A.W. et al. (eds.): Vitamin D. Basic Research and its Clinical Application. New York: W. de Gruyter, 1979, pp. 1209–1216.
Ritz, E., Malluche, H.H., Krempien, B. et al.: Pathogenesis of renal osteodystrophy: Roles of phosphate and skeletal resistance to PTH. In Advances in Experimental Medicine 103: 423–437, 1978.
Massry, S.G., Ritz, E. and Verberckmoes, R.: Role of phosphate in the genesis of secondary hyperparathyroidism of renal failure. Nephron 18: 77–81, 1977.
Bricker, N.S., Slatopolsky, E., Reiss, E. et al.: Calcium, phosphorus and bone in renal disease and transplantation. Arch. Int. Med. 123: 543–554, 1969.
Slatopolsky, E., Caglar, S., Pennell, J.P. et al.: On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog. J. Clin. Invest. 50: 492–500, 1971.
Levine, B.S. and Coburn, J.W.: Physiology of the vitamin D endocrine system and disorders of altered vitamin D metabolism. In: Brenner, B.M. and Stein, J.H. (eds.): Contemporary Issues in Nephrology, Vol. 4. Hormonal Function and the Kidney. New York: Churchill Livingstone, 1979, pp. 215–251.
Llach, F., Massry, S.G., Singer, F.R. et al.: Skeletal resistance to endogenous parathyroid hormone in patients with early renal failure. A possible cause for secondary hyperparathyroidism. J. Clin. Endocr. Metab. 41: 339–345, 1975.
Reiss, E., Canterbury, J.M., Bercovitz, M.A. et al.: The role of phosphate in the secretion of parathyroid hormone in man. J. Clin. Invest. 49: 2146–2149, 1970.
Rutherford, W.E., Bordier, P., Marie, P. et al.: Phosphate control and 25-hydroxycholecalciferol administration in preventing experimental renal osteodystrophy in the dog. J. Clin. Invest. 60: 332–341, 1977.
Kaplan, M., Canterbury, J., Bourgoignie, J. et al.: Reversal of hyperparathyroidism in response to dietary phosphorus restriction in uremic dog. Kidney Int. 15: 43–48, 1979.
Slatopolsky, E. and Bricker, N.S. The role of phosphorus restriction in the prevention of secondary hyperparathyroidism in chronic renal disease. Kidney Int. 4: 141–146, 1973.
Jacob, A.I., Canterbury, J.M., Gavellas, G. et al.: Effect of Cimetidine on calcium and phosphate homeostasis in normal and uremic dogs. Clin. Res. 28, 450A, 1980.
Swenson, R.S., Weisinger, J.R., Ruggeri, J.L. et al.: Evidence that parathyroid hormone is not required for phosphate homeostasis in renal failure. Metab. Clin. End. 24: 199–204, 1975.
Tröhler, U., Bonjour, J.P. and Fleisch, H. Inorganic phosphate homeostasis. Renal adaptation to the dietary intake in intact and thyroparathyroidectomized rats. J. Clin. Invest. 57: 264–273, 1976.
Steele, T.H. and DeLuca, F. Influence of dietary phosphorus on renal phosphate reabsorption in the parathyroidectomized rat. J. Clin. Invest. 57: 867–874, 1976.
Sherwood, L.M., Mayer, G.P., Ramberg, C.F., Jr. et al.: Regulation of parathyroid hormone secretion: proportional control by calcium, lack of effect of phosphate. Endocr. 83: 1043–1052, 1969.
Massry, S.G., Coburn, J.W., Lee, D.B. et al.: Skeletal resistance to parathyroid hormone in renal failure. Studies in 105 human subjects. Ann. Int. Med. 78: 357–364, 1973.
Massry, S.G., Stein, R., Garty, G. et al.: Skeletal resistance to the calcemic action of parathyroid hormone in uremia: role of l,25(OH)2D3. Kidney Int. 9: 467–474, 1976.
Massry, S.G., Dua, S., Garty, J. et al.: Role of uremia in the skeletal resistance to the calcemic action of parathyroid hormone. Min. Electrolyte Metab. 1: 172–180, 1978.
Kaplan, M.A., Canterbury, J.M., Gavellas, G. et al.: The calcemic and Phosphaturie effects of parathyroid hormone in the normal and uremic dog. Metab. 27: 1785–1792, 1978.
Massry, S.G., Tumas, S., Dua, S. and Goldstein, D.A.: Reversal of skeletal resistance to parathormone in uremia by vitamin D metabolites. J. Lab. Clin. Med. 94: 152–158, 1979.
Wills, M.R. and Jenkins, M.V.: The effect of uremic metabolites on parathyroid extract — induced bone resorption in vitro. Clin. Chim. Acta 73: 121–125, 1976.
Raisz, L.G. and Niemann, I.: Effect of phosphate, calcium and magnesium on bone resorption and hormonal responses in tissue culture. Endocr. 85: 446–453, 1969.
Habener, J.F. and Potts, J.T.: Biosynthesis of parathyroid hormone. N. Engl. J. Med. 299: 580–585 and 635–644, 1978.
Hruska, K.A., Kapelman, R., Rutherford, W.E. et al.: Metabolism of immunoreactive parathyroid hormone in the dog. J. Clin. Invest. 56: 39–48, 1975.
Freitag, J.J., Martin, K., Hruska, K.A. et al.: Impaired parathyroid hormone metabolism in patients with chronic renal failure. N. Engl. J. Med. 298: 29–32, 1978.
Martin, K., Hruska, K.A., Freitag, J.J. et al.: The peripheral metabolism of parathyroid hormone. N. Engl. J. Med. 301: 1092–1098, 1979.
Bellorin-Font, Martin, K.J., Freitag, J.J. et al.: Altered adenylate cyclase kinetics in hyperfunctioning human glands. Comparison with normal human and bovine parathyroid tissue. J. Clin. Invest. In press.
Canterbury, J.M., Lerman, S., Claflin, A.J. et al.: Inhibition of parathyroid hormone secretion by 25-hydroxycholecalciferol and 24,25 dihydroxycholecalciferol in the dog. J. Clin. Invest. 51: 1375–1383, 1978.
Canterbury, J.M., Gavellas, G., Bourgoignie, J. et al.: In-vivo suppression of parathyroid hormone secretion by 24,25 dihydroxycholecalciferol in hyperparathyroid dogs. In: Norman, A.W. et al. (eds.): Vitamin D. Basic Research and its Clinical Application. New York: W. de Gruyter, 1979, pp. 297–305.
Canterbury, J., Gavellas, G., Bourgoignie, J. et al.: Metabolic consequences of oral administration of 24,25(OH)2D3 to uremic dog. J. Clin. Invest. 65: 571–576, 1980.
Care, A.D., Pickard, D.W., Papapoulos, S.E. et al.: Inhibitory effect of 25,26-dihydroxycholecalciferol on the rate of secretion of parathyroid hormone in goats. J. Endocr. 78: 303–304, 1978.
Golden, P., Mazey, R., Greenwalt, A. et al.: Vitamin D: A direct effect on the parathyroid gland? Min. Electrolyte Metab. 2: 1–6, 1979.
Tanaka, Y., DeLuca, H.F., Ghazarian, J.G. et al.: Effect of vitamin D and its metabolites on serum parathyroid hormone levels in the rat. Min. Electrolyte Metab. 2: 20–25, 1979.
DeLuca, H.F.: Vitamin D and calcium transport. Annals N.Y. Acad. Sci. 356–376, 1978.
DeLuca, H.F.: Vitamin D metabolism and function. Arch. Int. Med. 138: 836–847, 1978.
Haussler, M.R. and McCain, T.: Basic and medical concepts related to vitamin D metabolism and action. N. Engl. J. Med. 297: 974–983 and 1041–1050, 1977.
Taylor, C.M.: 24,25-dihydroxyvitamin D in human serum. In: Norman, A.W. et al. (eds.): Vitamin D. Basic Research and its Clinical Application. New York: W. de Gruyter, 1979, pp. 197–204.
Russell, R.G.G., Kanis, J.A., Smith, R. et al.: Physiological and pharmacological aspects of 24,25-dihydroxycholecalciferol in man. In: Advances in Experimental Medicine 103: 487–504, 1978.
Horst, R.L., Shepard, R.M., Jorgensen, N.A. et al.: Assays of vitamin D and its metabolites. In: Norman, A.W. et al. (eds.): Vitamin D. Basic Research and its Clinical Application. New York: W. de Gruyter, 1979, pp. 213–220.
Lund, B., Clausen, E., Friedberg, M. et al.: Serum 1,25-dihydroxycholecalciferol in anephric, haemodialyzed and kidney transplanted patients. Effect of vitamin D supplement. Nephron 25–33, 1980.
Liu, S.H. and Chu, H.I.: Studies of calcium and phosphorus metabolism with special reference to pathogenesis and effect of dihydrotachysterol (AT10) and iron. Medicine (Baltimore) 22: 103–162, 1943.
Malluche, H.H., Werner, E. and Ritz, E.: Intestinal absorption of calcium and wholebody calcium retention in incipient and advanced renal failure. Min. Electrolyte Metab. 1: 263–270, 1978.
Kanis, J.A., Keyner, G., Russell, R.G.G. et al.: Biological effects of 24,25-dihydroxycholecalciferol in man. In: Norman, A.W. et al. (eds.): Vitamin D. Biochemical, chemical and clinical aspects related to calcium metabolism. New York: W. de Gruyter, 1977, pp. 793–796.
Llach, F., Brickman, A.S., Singer, F.R. et al.: 24,25-dihydroxycholecalciferol, a vitamin D sterol with qualitatively unique effects in uremic man. Metab. Bone Dis. and Rel. Res. 2: 11–15, 1979.
Malluche, H.H., Goldstein, D.A. and Massry, S.G. Osteomalacia and hyperparathyroid bone disease in patients with nephrotic syndrome. J. Clin. Invest. 73: 494–500, 1979.
Slatopolsky, E., Rutherford, W.E., Rosenbaum, R. et al.: Hyperphosphatemia. Clin. Nephrol. 7: 138–146, 1977.
Goldsmith, R., Furszyfer, J., Johnson, W.J. et al.: Control of secondary hyperparathyroidism during long-term hemodialysis. Am. J. Med. 50: 692–699, 1971.
Bouillon, R., Verberckmoes, R. and DeMoor, P.: Influence of dialysate calcium concentration and vitamin D on serum parathyroid hormone during repetitive dialysis. Kidney Int. 7: 422–432, 1975.
Goldsmith, R.S. and Johnson, W.J. Role of phosphate depletion and high dialysate calcium in controlling dialytic renal osteodystrophy. Kidney Int. 4: 154–161, 1973.
Clarkson, E.M., Eastwood, J.B., Koutsaimanis, K.G. et al.: Net intestinal absorption of calcium in patients with chronic renal failure. Kidney Int. 3: 258–263, 1973.
Goldstein, D.A., Malluche, H.H. and Massry, S.G. Management of renal osteodystrophy with 1,25(OH)2D3. I. Effects on clinical, radiographic, and biochemical parameters. Min. Electrolyte Metab. 2: 35–47, 1979.
Malluche, H.H., Goldstein, D.A. and Massry, S. Management of renal osteodystrophy with 1,25(OH)2D3. II. Effects on histopathology of bone: evidence for healing osteomalacia. Min. Electrolyte Metab. 2: 48–55, 1979.
Fournier, A., Bordier, P, Gueris, J. et al.: Comparison of 1α-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy — greater effects of 25-hydroxycholecalciferol on bone mineralization. Kidney Int. 15: 196–204, 1979.
Hodsman, A.B., Sherrard, D.J., Wong, E.G.C. et al.: Vitamin D resistant osteomalacia without secondary hyperparathyroidism in dialysis patients. Clin. Res. 28: 560A, 1980.
Coburn, J.W., Wong, E.G.C, Sherrard, D.J. et al.: Use of 24, 25-dihydroxyvitamin D3 in dialysis osteomalacia: preliminary results. Clin. Res. 28: 532A, 1980.
Eastwood, J.B., de Wardener, H.E., Gray, R.W. et al.: Normal plasma 1,25-(OH)2 — Vitamin-D concentrations in nutritional osteomalacia. Lancet 1: 1377–1378, 1979.
Bell, N.H. and Stern, P.H. Hypercalcemia and increases in serum hormone value during prolonged administration of 1,25-dihydroxyvitamin D. N. Engl. J. Med. 298: 1241–1243, 1978.
Christiansen, C., Redbro, P., Christensen, M.S. et al.: Deterioration of renal function during treatment of chronic renal failure with 1,25 dihydroxycholecalciferol. Lancet 2: 700–703, 1978.
Nielsen, H.E., Romer, F.K., Meisen, F. et al.: 1α-hydroxy vitamin D3 treatment of non-dialyzed patients with chronic renal failure. Effects on bone, mineral metabolism and kidney function. Clin. Nephrol. 13: 103–108, 1980.
Wilson, R.E., Hampers, C.L., Bernstein, D.S. et al.: Subtotal parathyroidectomy in chronic renal failure. A seven year experience in a dialysis and transplant program. Ann. Surgery 174: 640–652, 1971.
Wells, S.A., Gunnells, J.C., Shelburne, J.D. et al.: Transplantation of the parathyroid glands in man: clinical indications and results. Surgery 78: 34–43, 1975.
Schneider, A.B., Wells, S.A., Gunnells, J.C. et al.: Regulation of function of transplanted parathyroid glands. Am. J. Med. 63: 710–718, 1977.
Cordeil, L.J., Maxwell, J.G. and Warden, G.D. Parathyroidectomy in chronic renal failure. Am. J. Surgery 138: 951–956, 1979.
Caro, J.F., Besarab, A., Burke, J.F. et al.: A possible role for propranolol in the treatment of renal osteodystrophy. Lancet 2: 451–454, 1978.
Coevoet, B., Andrejak, M., Desplan, C. et al.: Acute effects of propranolol and metoprolol on plasma concentrations of parathyroid hormone and calcitonin in uremic patients. In: Thurm, R.H. (ed.): Essential Hypertension. Chicago: Yearbook Medical Publ., 1979, pp. 219–229.
Caro, J.F., Castro, J.H. and Glennon, J.A.: Effect of long-term propranolol administration on parathyroid hormone and calcium concentration in primary hyperparathyroidism. Ann. Int. Med. 91: 740–741, 1979.
Jacob, A.I., Lanier, D., Jr., Canterbury, J.M. et al. Reduction of serum parathyroid hormone levels in uremic patients. N. Engl. J. Med. 302: 671–674, 1980.
Kukreja, S.C., Williams, G.A., Hargis, G.K. et al.: Dual control of suppressibility of parathyroid hormone by calcium and by beta-adrenergic blockade. Min. Electrolyte Metab. 2: 316–322, 1979.
Brown, E.M., Gardner, D., Windeck, R.A. et al.: B. Adrener-gically stimulated 3f, 5f monophosphate accumulation in and parathyroid hormone release from dispersed human parathyroid cells. J. Clin. Endocr. Metab. 48: 618–626, 1976.
Kukreja, S.C., Johnson, P.A., Ayala, G. et al.: Role of calcium and beta-adrenergic system in control of parathyroid hormone secretion. Proc. Soc. Exp. Biol. Med. 151: 326–328, 1976.
Longley, R.S., Hargis, G.K., Bowser, E.N. et al.: Parathyroid hormone and calcitonin secretion: role of histamine H2 receptors. Clin. Res. 28: 398A, 1980.
Brown, E.M.: Histamine receptors in parathyroid adenomas. Clin. Res. 28: 388A, 1980.
Williams, G.A., Longley, R.S., Hargis, G.K. et al.: Effect of histamine on secretion of parathyroid hormone. Clin. Res. 27: 794A, 1979.
Fischer, J.A. and Blum, J.W.: Noncalcium control of parathyroid hormone secretion. Min. Electrolyte Metab. 3: 158–166, 1980.
Lanier, D., Favre, H., Jacob, A.I. et al.: Cimetidine therapy for severe hypercalcemia in two chronic hemodialysis patients. Ann. Int. Med. In press.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1981 Plenum Press, New York
About this chapter
Cite this chapter
Bourgoignie, J.J. (1981). Renal Osteodystrophy: Pathogenesis, Prevention and Treatment. In: Strauss, J. (eds) Pediatric Nephrology. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-8804-3_31
Download citation
DOI: https://doi.org/10.1007/978-1-4684-8804-3_31
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-8806-7
Online ISBN: 978-1-4684-8804-3
eBook Packages: Springer Book Archive